Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

ClinicalTrials.gov ID: NCT04606914

Public ClinicalTrials.gov record NCT04606914. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 6, 2026, 2:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer Who Are Folate Receptor α Positive

Study identification

NCT ID: NCT04606914
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: University of Alabama at Birmingham; Other
Enrollment: 70 participants

Conditions and interventions

Conditions

Interventions

mirvetuximab soravtansine (MIRV; IMGN853) Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 26, 2021
Primary completion: May 30, 2026
Completion: May 30, 2028
Last update posted: Sep 7, 2025

2021 – 2028

United States locations

U.S. sites: 9
U.S. states: 8
U.S. cities: 9

Facility	City	State	ZIP	Site status
University of Alabama at Birmingham Womens & Infants Center	Birmingham	Alabama	35233	Recruiting
University of California San Francisco	San Francisco	California	94158	Recruiting
University of Minnesota - Masonic Cancer Center	Minneapolis	Minnesota	55455	Recruiting
Mayo Clinic	Rochester	Minnesota	55905	Recruiting
University of Mississippi Medical Center	Oxford	Mississippi	36607	Recruiting
Ohio State University	Columbus	Ohio	43026	Recruiting
University of Oklahoma	Oklahoma City	Oklahoma	73104	Recruiting
Allegheny Health Network	Pittsburgh	Pennsylvania	15224	Recruiting
University of Virginia	Richmond	Virginia	23219	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04606914, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 7, 2025 · Synced May 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04606914 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →